AGI provides comprehensive pharmacokinetic (PK), toxicokinetic (TK), and pharmacodynamic (PD) study execution services to advance the safe and effective development of new therapeutics. Our capabilities span early dose-ranging through full IND-enabling studies, delivering the quantitative data necessary to characterize absorption, distribution, metabolism, excretion, and mechanism-of-action in translational models. Our dedicated GLP-compliant laboratories, advanced bioanalytical platforms, and highly experienced scientific staff generate high-quality data that withstands the highest levels of regulatory and sponsor scrutiny.

 

Each study is carefully designed to integrate biomarker readouts, safety margins, and efficacy measures, ensuring that clients receive not only the required regulatory datasets but also actionable insights to guide decision-making and program strategy. By combining technical expertise with robust infrastructure and a deep commitment to animal welfare, AGI helps sponsors accelerate development timelines, reduce risk, and strengthen the reproducibility of results. Our PK, TK, and PD programs are trusted by academic researchers, global pharmaceutical companies, and government partners alike.